501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Receives
Notice of Allowance for Detection
of Molecules -
FAIMS
U.S.
Patent
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- May
4, 2021
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC PINK: BLOZF) (the
"Company" or
"Cannabix")
developer
of the Cannabix Marijuana Breathalyzer devices
for law
enforcement and the workplace, reports that it has received a notice of
allowance
from the
United States Patent and
Trademark Office (USPTO) for patent
application, No. 17/019728
entitled,
"Apparatus and Methods
for Detection of Molecules".
This
Track 1 patent application is centered on
innovations
made by
Cannabix with its
FAIMS
(field
asymmetric waveform ion mobility spectrometry)
based
marijuana
breathalyzer technology. This patent application is the culmination
of research and development work conducted by Cannabix scientists
and engineers in the areas of ion mobility spectrometry,
non-volatile molecule sampling and fluid
dynamics. These
developments
will
provide
utility in several
areas
related to detection of molecules in breath.
Cannabix is using its
FAIMS technology to isolate and detect ?9-tetrahydrocannabinol
("THC"),
a non-volatile compound, in breath. The Cannabix FAIMS marijuana
breathalyzer device uses ion mobility filtering techniques (related
to mass spectrometry – the gold standard analytical technique for
molecular detection). The Cannabix device
has been designed and built in a series of modules that together
allow for sample intake, ionization, filtering and detection – all
done under atmospheric pressure. In addition, the
device has the ability to couple directly
to a mass spectrometer
in order to validate its detector responses.
It should be noted
that a notice
of allowance from the USPTO does
not constitute a grant of patent. The Company will report on
future material developments regarding its "Apparatus and Methods
for Detection of Molecules" patent application
in due course.
The Company has
been steadily
growing
its intellectual property (IP)
portfolio
over
recent months. In
April, the Company
received
a notice
of allowance for its
patent
application, No. 2887841 entitled, "Cannabis Drug Detection Device"
from the
Canadian
Intellectual Property Office (CIPO). In addition,
the
Company was granted a granted patent No.
14/689434 entitled, "Cannabis Drug Detection Device"
from the
USPTO in January 2021. The newly received
notice of
allowance
from the
USPTO for its FAIMS related
patent application builds on this IP momentum.
The Company expects
to ship its THCBA to a clinic in
the Northwestern,
U.S. for beta
testing in May.
The
collaborating clinic has a robust drug testing operation and is one
of the top drug testing providers to employers within its respective
state. The
beta
testing is focussed
on
improving
user
experience through testing and
feedback
and
training
the device's machine learning database.
About Cannabix
Technologies Inc.
Cannabix Technologies
Inc. is a developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law
enforcement to identify
recent marijuana use that better
aligns with impairment.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix Technologies
Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.